Senseonics Announces a Positive Coverage Decision for Eversense CGM from Health Care Service Corporation - Blue Cross Blue Shield of Illinois, Montana, New Mexico, Oklahoma and Texas https://t.co/UlP7eIpiWZ
Are you living with diabetes, or know someone who is? Do you have a desire to help others learn more about the day-to-day life with diabetes? Be sure to check out our community page.
https://t.co/VSSwDBM7Mk
Are you living with diabetes, or know someone who is? Do you have a desire to help others learn more about the day-to-day life with diabetes? Be sure to check out our community page.
https://t.co/VSSwDBM7Mk
Join us August 28th & 29th for one of two Facebook LIVE events with our Eversense Unstoppable Ambassadors: news anchor Darrell Greene @t1d_g, powerlifter Chris Ruden @chrisruden and author Laura Kronen @beyouonlybetter
Register here:
https://t.co/O3gCISSGHG
Join us August 28th & 29th for one of two Facebook LIVE events with our Eversense Unstoppable Ambassadors: news anchor Darrell Greene @t1d_g, powerlifter Chris Ruden @chrisruden and author Laura Kronen @beyouonlybetter
Register here:
https://t.co/O3gCISSGHG
Geo-Med and The Veterans Affairs Medical Center in Omaha, Nebraska is the first VA in the country to offer EversenseCGM. Now, veterans with diabetes in Omaha (and across the country) can experience the freedom of using an up to 3-month CGM system. #CGM ... https://t.co/KweBoVYLCK
Eversense is proud to support @BeyondType1's @typeonerun initiative.
If you have type 1 diabetes and you like running or would like to start running, join in!
To get started, visit https://t.co/BHNJzjfcsS
If you missed the talk on User Acceptance of the Eversense® CGM System in a Home Use Setting: The House Study by Dr. Magnus Londahl at ADA 2019, you can read the abstract here: https://t.co/9juibRgl0t
If you missed the poster sessions at ADA, click the link below to view the abstract: Post Market Clinical Follow-Up (PMCF) Registry to Demonstrate the Long Term Safety of the Eversense CGM System, that was presented at 2019 ADA. https://t.co/Jsuo6HVq6n
Senseonics Announces FDA Approval for a Non-Adjunctive Indication (Dosing Claim) for the Eversense® 90-day CGM System https://t.co/Jk0J9HmBir #Senseonics#EversenseCGM